NCT01272089View on ClinicalTrials.gov

A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis

PHASE4CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Allergic Conjunctivitis
Interventions
DRUG

Olopatadine Hydrochloride Ophthalmic Solution, 0.2%

Olopatadine Hydrochloride Ophthalmic Solution, 0.2%, one drop once a day for one week

Trial Locations (1)

700020

Kolkata

Sponsors

Lead Sponsor

Alcon Research
All Listed Sponsors
lead

Alcon Research

INDUSTRY

NCT01272089 - A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis | Biotech Hunter | Biotech Hunter